High-dose Ascorbic Acid Synergizes with Anti-PD1 Therapy in Non-small Cell Lung Cancer and Models

Overview

Journal Front Immunol

Date 2025 Feb 3

PMID 39896806

Authors

Hak Su Kim

Seung-Hyun Kwon

Ok Kyung Choi

Taekyu Lim

Affiliations

Soon will be listed here.

Abstract

Introduction: Immune checkpoint inhibitors(ICIs) targeting programmed cell death protein 1 (PD1) confer significant survival benefits to patients with non-small cell lung cancer (NSCLC). However, there remains a substantial unmet need to identify therapeutic approaches to overcome resistance and provide benefits to these patients. High-dose ascorbic acid (AA) acts synergistically with many standard anticancer treatments. However, little is known about the effect of high-dose AA on improving the efficacy of anti-PD1 inhibitors in NSCLC. This study aimed to elucidate the effects of high-dose AA on anti-PD1 immunotherapy in NSCLC.

Methods: The combined effects of high-dose AA and anti-PD1 were investigated using a coculture model of H460 cells and CD8+ T cells and an LLC1 lung cancer syngeneic mouse model. To investigate the molecular mechanism, tumor tissues from mice were analyzed by comprehensive proteomic profiling using nano-LC-ESI-MS/MS.

Results: Pretreatment with a high dose of AA led to enhanced the sensitivity to the cytotoxicity of CD8+ T cells derived from healthy donor for H460 cells. Additionally, the combination of anti-PD1 and high-dose AA significantly increased CD8+ T cell cytotoxicity in H460 cells. The combination of anti-PD1 and high-dose AA showed dramatic antitumor effects in a syngeneic mouse model of lung cancer by significantly reducing tumor growth and increasing CD8+ T cell-dependent cytotoxicity and macrophage activity. Comprehensive protein analysis confirmed that high-dose AA in anti-PD1-treated tumor tissues enhanced the antitumor effects by regulating various immune-related mechanisms, including the B cell and T cell receptor signaling pathways, Fc gamma R-mediated phagocytosis, and natural killer (NK) cell-mediated cytotoxicity.

Discussion: Our results suggest that high-dose AA may be a promising adjuvant to potentiate the efficacy of anti-PD1 immunotherapy.

Citing Articles

Focusing on Formyl Peptide Receptors after Traumatic Spinal Cord Injury: from Immune Response to Neurogenesis.

Pu Z, Luo D, Shuai B, Xu Y, Liu M, Zhao J Neurochem Res. 2025; 50(2):98.

PMID: 39920516 DOI: 10.1007/s11064-025-04347-5.

References

Bottger F, Valles-Marti A, Cahn L, Jimenez C . High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. J Exp Clin Cancer Res. 2021; 40(1):343. PMC: 8557029. DOI: 10.1186/s13046-021-02134-y. View

Bahar M, Kim H, Kim D . Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023; 8(1):455. PMC: 10725898. DOI: 10.1038/s41392-023-01705-z. View

Chen Q, Espey M, Krishna M, Mitchell J, Corpe C, Buettner G . Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005; 102(38):13604-9. PMC: 1224653. DOI: 10.1073/pnas.0506390102. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Magri A, Germano G, Lorenzato A, Lamba S, Chila R, Montone M . High-dose vitamin C enhances cancer immunotherapy. Sci Transl Med. 2020; 12(532). DOI: 10.1126/scitranslmed.aay8707. View

Burns J . Missing step in man, monkey and guinea pig required for the biosynthesis of L-ascorbic acid. Nature. 1957; 180(4585):553. DOI: 10.1038/180553a0. View

Creagan E, MOERTEL C, OFallon J, SCHUTT A, Oconnell M, Rubin J . Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979; 301(13):687-90. DOI: 10.1056/NEJM197909273011303. View

Zhao X, Liu M, Li C, Liu X, Zhao J, Ma H . High dose Vitamin C inhibits PD-L1 by ROS-pSTAT3 signal pathway and enhances T cell function in TNBC. Int Immunopharmacol. 2023; 126:111321. DOI: 10.1016/j.intimp.2023.111321. View

Schoenfeld J, Sibenaller Z, Mapuskar K, Wagner B, Cramer-Morales K, Furqan M . O and HO-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017; 32(2):268. DOI: 10.1016/j.ccell.2017.07.008. View

10.

Mayland C, Bennett M, Allan K . Vitamin C deficiency in cancer patients. Palliat Med. 2005; 19(1):17-20. DOI: 10.1191/0269216305pm970oa. View

11.

Young J, Zuchner S, Wang G . Regulation of the Epigenome by Vitamin C. Annu Rev Nutr. 2015; 35:545-64. PMC: 4506708. DOI: 10.1146/annurev-nutr-071714-034228. View

12.

Kim S, Nam Y, Kim M, Kwon S, Jeon J, Shin S . Proteomic analysis for the effects of non-saponin fraction with rich polysaccharide from Korean Red Ginseng on Alzheimer's disease in a mouse model. J Ginseng Res. 2023; 47(2):302-310. PMC: 10014184. DOI: 10.1016/j.jgr.2022.09.008. View

13.

Manning J, Mitchell B, Appadurai D, Shakya A, Pierce L, Wang H . Vitamin C promotes maturation of T-cells. Antioxid Redox Signal. 2012; 19(17):2054-67. PMC: 3869442. DOI: 10.1089/ars.2012.4988. View

14.

Cameron E, PAULING L . Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978; 75(9):4538-42. PMC: 336151. DOI: 10.1073/pnas.75.9.4538. View

15.

Singhal A, Li B, OReilly E . Targeting KRAS in cancer. Nat Med. 2024; 30(4):969-983. PMC: 11845254. DOI: 10.1038/s41591-024-02903-0. View

16.

Cameron E, PAULING L . Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976; 73(10):3685-9. PMC: 431183. DOI: 10.1073/pnas.73.10.3685. View

17.

Luchtel R, Bhagat T, Pradhan K, Jacobs Jr W, Levine M, Verma A . High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. Proc Natl Acad Sci U S A. 2020; 117(3):1666-1677. PMC: 6983418. DOI: 10.1073/pnas.1908158117. View

18.

Chen Q, Espey M, Sun A, Pooput C, Kirk K, Krishna M . Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008; 105(32):11105-9. PMC: 2516281. DOI: 10.1073/pnas.0804226105. View

19.

Huijskens M, Walczak M, Koller N, Briede J, Senden-Gijsbers B, Schnijderberg M . Technical advance: ascorbic acid induces development of double-positive T cells from human hematopoietic stem cells in the absence of stromal cells. J Leukoc Biol. 2014; 96(6):1165-75. DOI: 10.1189/jlb.1TA0214-121RR. View

20.

Tsai P, Lai Y, Manne R, Tsai Y, Sarbassov D, Lin H . Akt: a key transducer in cancer. J Biomed Sci. 2022; 29(1):76. PMC: 9526305. DOI: 10.1186/s12929-022-00860-9. View